Oramed Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly13.2MTarget: Maintain sufficient cash reserves through at least mid-2027
Total Stockholders' Equity Quarterly238.3K
Operating Loss Quarterly-3.7MTarget: Narrowing operating loss through disciplined expense management
Watch Items
- Lifeward Strategic Transaction IntegrationTrigger: Closing of the transaction and transfer of POD technology platformAction: Monitor Lifeward's product sales (ReWalk and AlterG) and the 4% net sales royalty stream
- ORMD-0801 Phase 2 Clinical TrialTrigger: Commencement of the anticipated Phase 2 trial under clinical trial management agreementAction: Track patient enrollment milestones and clinical trial progress managed by Oramed
- Investment Portfolio Fair Value VolatilityTrigger: Significant fluctuations in the market value of Alpha Tau and Scilex holdingsAction: Assess impact on non-operating net income and overall asset valuation
Research as of 19 Jun 2026